共 86 条
- [1] Inwards DJ(2011)Initial therapy of mantle cell lymphoma Ther Adv Hematol 2 381-392
- [2] Witzig TE(2019)Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma Curr Oncol 26 e233-e240
- [3] Owen C(2017)Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004) J Hematol Oncol 10 171-62
- [4] Berinstein NL(2018)Guideline for the management of mantle cell lymphoma Br J Haematol 182 46-e71
- [5] Christofides A(2019)Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy Haematologica 104 e68-688
- [6] Sehn LH(2020)Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy Br J Haematol 189 684-587
- [7] Wang M(2018)Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib Br J Haematol 183 578-1563
- [8] Schuster SJ(2016)Postibrutinib outcomes in patients with mantle cell lymphoma Blood 127 1559-759
- [9] Phillips T(2022)Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study Br J Haematol 202 749-1342
- [10] McKay P(2020)KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma N Engl J Med 382 1331-3067